Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Carisma Therapeutics Inc. (CARM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: CARM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -75.07% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.62M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 152837 | Beta 2.86 | 52 Weeks Range 0.20 - 2.05 | Updated Date 04/2/2025 |
52 Weeks Range 0.20 - 2.05 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-31 | When Before Market | Estimate -0.1625 | Actual -0.42 |
Profitability
Profit Margin - | Operating Margin (TTM) -388.3% |
Management Effectiveness
Return on Assets (TTM) -56.08% | Return on Equity (TTM) -362.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -13940600 | Price to Sales(TTM) 0.47 |
Enterprise Value -13940600 | Price to Sales(TTM) 0.47 | ||
Enterprise Value to Revenue 0.43 | Enterprise Value to EBITDA -0.06 | Shares Outstanding 41750100 | Shares Floating 30222486 |
Shares Outstanding 41750100 | Shares Floating 30222486 | ||
Percent Insiders 30.93 | Percent Institutions 30.13 |
Analyst Ratings
Rating 3.4 | Target Price 4.57 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Carisma Therapeutics Inc.
Company Overview
History and Background
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies. Founded in 2016, the company aims to revolutionize cancer treatment through engineered macrophages.
Core Business Areas
- Chimeric Antigen Receptor Macrophages (CAR-M): Development of CAR-M therapies to target solid tumors. This involves genetically engineering macrophages to express CARs that specifically recognize and destroy cancer cells.
Leadership and Structure
The company is led by Steven Kelly (CEO) and has a management team focused on research, development, and clinical operations. It operates with a structure common for biotech companies, emphasizing research and clinical trials.
Top Products and Market Share
Key Offerings
- CT-0508 (CAR-M therapy targeting HER2-expressing solid tumors): This is their lead product candidate, currently in Phase 1 clinical trials for HER2-overexpressing solid tumors. Market share data is not yet available due to its early stage. Competitors include companies developing HER2-targeted therapies, such as Roche (Herceptin) and other CAR-T cell therapies.
Market Dynamics
Industry Overview
The immunotherapy market is rapidly growing, with a focus on cell therapies for cancer treatment. The industry is characterized by high innovation and competition.
Positioning
Carisma Therapeutics Inc. is positioned as a pioneer in the CAR-M field, differentiating itself from CAR-T cell therapies by leveraging macrophages.
Total Addressable Market (TAM)
The TAM for cell therapies in oncology is expected to reach billions of dollars. Carisma is positioned to capture a portion of this market with its novel macrophage-based approach.
Upturn SWOT Analysis
Strengths
- Pioneering CAR-M technology
- Strong scientific team
- Early mover advantage in macrophage therapies
Weaknesses
- Early stage clinical development
- High cash burn rate
- Dependence on successful clinical trial outcomes
Opportunities
- Expanding CAR-M platform to other cancer targets
- Partnerships with larger pharmaceutical companies
- Positive clinical data driving market adoption
Threats
- Competition from established CAR-T cell therapies
- Clinical trial failures
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- Gilead (GILD)
- Novartis (NVS)
- Bristol Myers Squibb (BMY)
Competitive Landscape
Carisma Therapeutics Inc. is entering a competitive market with established players in cell therapy. Its CAR-M technology offers a novel approach, but it faces challenges in proving its efficacy and safety compared to CAR-T cell therapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by research and development progress.
Future Projections: Future growth is contingent on successful clinical trial outcomes and partnerships.
Recent Initiatives: Advancement of CT-0508 into Phase 1 clinical trials.
Summary
Carisma Therapeutics Inc. is a promising biotech company pioneering CAR-M therapy, offering a novel approach to cancer treatment. While still in early clinical stages, the company's innovative technology and strong scientific team position it for potential growth. However, it faces challenges regarding clinical trials and competition from more established therapies, highlighting the need for strong financial backing and successful clinical outcomes. The total addressable market is vast, and CARM is poised to take part.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
NVS
Novartis AG ADR
NVS
Novartis AG ADR
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (when available)
- Industry Reports
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Carisma Therapeutics Inc.
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2014-02-06 | President, CEO & Director Mr. Steven Kelly | ||
Sector Healthcare | Industry Biotechnology | Full time employees 107 | Website https://www.carismatx.com |
Full time employees 107 | Website https://www.carismatx.com | ||
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.